THERAPY DOSSIER · th-6703e5e578f6

TM-1, a thaliporphine derivative

Drug · No confident ChEMBL match; thaliporphine (aporphine alkaloid) derivative (research)

Evidence & regulatory context

Mechanism: No confident ChEMBL match; thaliporphine (aporphine alkaloid) derivative (research)
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25705683 ↗2015Reported benefit

Thaliporphine derivative improves acute lung injury after traumatic brain injury.

RatTBIControlled cortical impactSprague-DawleyMalen = 5 per group per time point, with 5 sham-operated ratsIntraperitoneal10 mg/kg in 0.1 mL3 h or 4 h after traumatic brain injury

Model: Controlled cortical impact traumatic brain injury through a craniotomy, impact velocity 4 m/s and deformation depth 2 mm below the dura, with resulting acute lung injury

TM-1 given at 3 or 4 h after injury significantly reduced the lung wet to dry weight ratio and lung injury score at both 8 and 24 h, and attenuated the injury-induced rise in aquaporin 1 and aquaporin 4 mRNA and protein. Lung injury score and wet to dry weight ratio were positively correlated (r =…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…